ArticleBMC surgery2025
Prognostic factors affecting survival in patients with duodenal adenocarcinoma and isolated liver metastases: a retrospective study.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aimed to identify the prognostic factors affecting survival among patients with duodenal adenocarcinoma (DAC) and isolated hepatic metastases (HM).
methodsWe conducted a retrospective analysis of clinical data from 51 patients treated for DAC and HM from January 2012 to January 2018. The Kaplan-Meier method and log-rank test were used for survival analysis. The Cox proportional hazards regression model was utilized for multivariate analysis.
resultsThirty-nine patients had synchronous HM, and 12 patients exhibited metachronous HM. Median overall survival (mOS) for patients with synchronous HM was 6.8 months, versus 45.9 months for those with metachronous HM (P < 0.001). mOS for the patients who received first-line chemotherapy was 18.9 months, compared with 4.4 months for the patients who did not undergo first-line chemotherapy (P < 0.001). Multivariate analysis identified the timing of HM detection and the receipt of first-line chemotherapy as independent prognostic factors. Subgroup analysis revealed that among patients with synchronous HM, mOS for patients who underwent primary tumor resection was 16.9 months, compared with 3.5 months for those who did not undergo resection (P < 0.001).
conclusionThe timing of detection of HM and the receipt of first-line chemotherapy are independent prognostic factors for patients with DAC and isolated HM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.